Preparation and biological evaluation of ethionamide-mesoporous silicon nanoparticles against Mycobacterium tuberculosis

• Type: Article in International Scientific Journal
• Date: 2017

Authors

Nuno Vale (Author) ICBAS; Correia, A (Author) Other; Silva, S (Author) Other; Figueiredo, P (Author) Other; Mäkilä, E (Author) Other; Salonen, J (Author) Other; Hirvonen, J (Author) Other; Pedrosa, J (Author) Other; Santos, HA (Author) Other; Fraga, A (Author) Other

Journal

Title: Bioorganic and Medicinal Chemistry Letters

Vol. 27

Pages: 403-405

ISSN: 0960-894X

Publisher: Elsevier

Indexing

Scopus - 10 Citations

Other information

Authenticus ID: P-00N-EEX

DOI: 10.1016/j.bmcl.2016.12.060

Abstract (EN): Ethionamide (ETH) is an important second-line antituberculosis drug used for the treatment of patients infected with multidrug-resistant Mycobacterium tuberculosis. Recently, we reported that the loading of ETH into thermally carbonized-porous silicon (TCPSi) nanoparticles enhanced the solubility and permeability of ETH at different pH-values and also increased its metabolization process. Based on these results, we synthesized carboxylic acid functionalized thermally hydrocarbonized porous silicon nanoparticles (UnTHCPSi NPs) conjugated with ETH and its antimicrobial effect was evaluated against Mycobacterium tuberculosis strain H37Rv. The activity of the conjugate was increased when compared to free-ETH, which suggests that the nature of the synergy between the NPs and ETH is likely due to the weakening of the bacterial cell wall that improves conjugate-penetration. These ETH-conjugated NPs have great potential in reducing dosing frequency of ETH in the treatment of multidrug-resistant tuberculosis (MDR-TB). © 2016 Elsevier Ltd

Language: English

Type (Professor's evaluation): Scientific